Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

CNSP

Cns Pharmaceuticals Inc

Jun 18 • 04:00PM ET

0.8318

Dollar change +0.0028
Percentage change 0.34	%

Healthcare • Biotechnology • USA • NASD

Peers: IMMP SLS VTVT CAPR AVTX BTAI OTLK PCRX BLRX KPTI

| Held by: VXF

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-352.42	Insider Own	0.80%	Shs Outstand	5.46M	Perf Week	-10.56%
Market Cap	4.54M	Forward P/E	-	EPS next Y	-1.38	Insider Trans	0.00%	Shs Float	5.42M	Perf Month	-35.52%
Income	-15.61M	PEG	-	EPS next Q	-0.80	Inst Own	0.74%	Short Float	3.36%	Perf Quarter	-78.17%
Sales	0.00M	P/S	-	EPS this Y	41.95%	Inst Trans	-2.87%	Short Ratio	0.11	Perf Half Y	-83.83%
Book/sh	3.73	P/B	0.22	EPS next Y	93.88%	ROA	-202.65%	Short Interest	0.18M	Perf Year	-99.40%
Cash/sh	2.39	P/C	0.35	EPS next 5Y	67.95%	ROE	-477.53%	52W Range	0.77 - 200.00	Perf YTD	-86.18%
Dividend Est.	-	P/FCF	-	EPS past 5Y	70.59%	ROIC	-142.34%	52W High	-99.58%	Beta	0.78
Dividend TTM	-	Quick Ratio	4.93	Sales past 5Y	-	Gross Margin	-	52W Low	7.81%	ATR (14)	0.11
Dividend Ex-Date	-	Current Ratio	4.93	EPS Y/Y TTM	95.95%	Oper. Margin	-	RSI (14)	32.65	Volatility	5.44% 3.69%
Employees	5	Debt/Eq	0.02	Sales Y/Y TTM	-	Profit Margin	-	Recom	2.00	Target Price	16.00
Option/Short	No / Yes	LT Debt/Eq	0.00	EPS Q/Q	99.84%	Payout	-	Rel Volume	0.08	Prev Close	0.83
Sales Surprise	-	EPS Surprise	21.00%	Sales Q/Q	-	Earnings	May 15 AMC	Avg Volume	1.71M	Price	0.83
SMA20	-16.50%	SMA50	-21.73%	SMA200	-80.13%	Trades		Volume	145,042	Change	0.34%

Date	Action	Analyst	Rating Change	Price Target Change
Dec-28-20	Downgrade	Ladenburg Thalmann	Buy → Neutral
Aug-24-20	Initiated	Ladenburg Thalmann	Buy	$11

Jun-05-25 08:05AM	CNS Pharmaceuticals' Chief Medical Officer, Sandra Silberman, MD, PhD to Present at the 2025 Brain Tumor Biotech Summit (ACCESSWIRE)
May-16-25 08:05AM	CNS Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Corporate Update (ACCESSWIRE)
May-13-25 09:35AM	CNS Pharmaceuticals Announces Pricing of $5 Million Public Offering Priced At-The-Market Under Nasdaq Rules (ACCESSWIRE) +12.40%
07:00AM	CNS Pharmaceuticals Acquires Orphan Drug Designation for Novel, Late Stage Abeotaxane, TPI 287 (ACCESSWIRE)
Apr-02-25 08:46AM	CNS Pharmaceuticals reports FY24 EPS ($38.87) vs. ($12,509.11) last year (TipRanks)
08:00AM	Loading…
Mar-25-25 08:00AM	CNS Pharmaceuticals Announces Primary Analysis of Berubicin in Second Line Treatment of Glioblastoma Multiforme (ACCESSWIRE) -51.78%
Feb-26-25 09:05AM	CNS Pharmaceuticals Provides Update on Current Cash Position and NASDAQ Listing (ACCESSWIRE)
Feb-20-25 09:00AM	CNS Pharmaceuticals to Present at the 18th Annual European Life Sciences CEO Forum (ACCESSWIRE) -10.50%
Feb-19-25 09:00AM	CNS Pharmaceuticals, Inc. Participates in the Virtual Investor 'Top 5 for '25' On-Demand Conference (ACCESSWIRE) -41.19%
08:30AM	CNS Pharmaceuticals Announces Reverse Stock Split (ACCESSWIRE)
Feb-18-25 09:00AM	CNS Pharmaceuticals to Present at 6th Glioblastoma Drug Development Summit (ACCESSWIRE)
Feb-10-25 08:00AM	CNS Pharmaceuticals to Present at the BIO CEO & Investor Conference (ACCESSWIRE) +10.46%
Dec-05-24 09:10AM	CNS Pharmaceuticals to Host Virtual Analyst and Investor Day on December 11, 2024 (ACCESSWIRE)
09:10AM	CNS Pharmaceuticals to Host Virtual Analyst & Investor Day on December 11, 2024 (ACCESS Newswire)
Nov-25-24 09:00AM	CNS Pharmaceuticals Presents Update from Ongoing Potentially Pivotal Study of Berubicin Compared with Lomustine in Adult Patients with Recurrent GBM (WHO Grade IV) After Failure of Standard First Line Therapy (ACCESSWIRE) -7.56%
08:55AM	Loading…
Nov-18-24 08:55AM	CNS Pharmaceuticals Announces Abstract Accepted for Poster Presentation at the 29th Annual Meeting of the Society for Neuro-Oncology (SNO 2024) (ACCESSWIRE) +14.18%
Nov-15-24 09:10AM	CNS Pharmaceuticals Reports Third Quarter 2024 Financial Results (ACCESSWIRE) -11.61%
Nov-04-24 09:15AM	CNS Pharmaceuticals Announces Virtual Investor KOL Connect Segment (ACCESSWIRE)
Nov-01-24 09:00AM	CNS Pharmaceuticals Granted Exception by Nasdaq to Regain Compliance with Minimum Bid Price Requirement (ACCESSWIRE)
Oct-23-24 02:50PM	CNS Pharmaceuticals Announces Pricing of $3 Million Registered Direct Offering of Common Stock Priced At-The-Market Under Nasdaq Rules (ACCESSWIRE) -10.02%
Oct-10-24 09:00AM	CNS Pharmaceuticals Participates in Virtual Investor KOL Connect Segment (ACCESSWIRE)
Oct-08-24 09:15AM	CNS Pharmaceuticals to Participate in the 2024 Healthcare Virtual Summit Presented by Maxim Group LLC (ACCESSWIRE) +11.37%
Sep-23-24 09:00AM	CNS Pharmaceuticals to Present at the 24th Annual Biotech in Europe Forum (ACCESSWIRE)
Sep-12-24 09:00AM	CNS Pharmaceuticals Regains Compliance with Nasdaq Equity Requirement (ACCESSWIRE) -5.58%
Sep-04-24 09:05AM	CNS Pharmaceuticals to Present at the H.C. Wainwright 26th Annual Global Investment Conference (ACCESSWIRE)
Sep-03-24 08:00AM	IBN Announces Latest Episode of The BioMedWire Podcast featuring John Climaco, CEO of CNS Pharmaceuticals Inc. (GlobeNewswire)
Aug-27-24 09:10AM	CNS Pharmaceuticals to Participate in at LIVE! with Webull Corporate Connect: Virtual Biotech Investment Webinar (ACCESSWIRE) -7.11%
Aug-22-24 09:15AM	CNS Pharmaceuticals to Participate in Virtual Investor CEO Connect Segment (ACCESSWIRE)
Aug-15-24 08:00AM	CNS Pharmaceuticals Reports Second Quarter 2024 Financial Results (ACCESSWIRE)
Jul-30-24 07:00AM	CNS Pharmaceuticals Expands Pipeline with In-License of Late Stage, Novel Potential Blood Brain Barrier Permeable Abeotaxane for Treatment of Brain Malignancies (ACCESSWIRE) -60.58%
09:05AM	Loading…
Jul-25-24 09:05AM	CNS Pharmaceuticals Announces Acceptance of Abstract for Poster Presentation at the 2024 SNO/ASCO CNS Cancer Conference (ACCESSWIRE)
Jul-16-24 09:15AM	CNS Pharmaceuticals to Participate in the Virtual Investor Closing Bell Series (ACCESSWIRE) -5.93%
Jul-11-24 07:29AM	Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday (InvestorPlace) +20.00%
Jul-03-24 11:10AM	CNS Pharmaceuticals Announces Pricing of Registered Direct Offering and Concurrent Private Placement (ACCESSWIRE) +15.87%
Jun-26-24 08:00AM	CNS Pharmaceuticals Announces Pricing of Registered Direct Offering and Concurrent Private Placement (ACCESSWIRE) -35.21%
Jun-14-24 03:11PM	CNS Pharmaceuticals Announces Pricing of Registered Direct Offering and Concurrent Private Placement (ACCESSWIRE) -22.93%
Jun-10-24 08:00AM	JTC Team Announces Participating Company Line-Up for the Virtual Investor Pitch Conference on June 17-18, 2024 (ACCESSWIRE) -27.72%
Jun-03-24 08:05AM	CNS Pharmaceuticals Announces Reverse Stock Split (ACCESSWIRE) -39.87%
May-20-24 08:30AM	CNS Pharmaceuticals to Present at Alliance Global Partner's 2024 Healthcare Company Showcase (ACCESSWIRE)
May-16-24 11:53AM	CNSP Stock Earnings: CNS Pharmaceuticals Reported Results for Q1 2024 (InvestorPlace) +12.68%
07:45AM	CNS Pharmaceuticals Reports First Quarter 2024 Financial Results (ACCESSWIRE)
Apr-23-24 09:00AM	CNS Pharmaceuticals to Present at the LSX World Congress 2024 (ACCESSWIRE) +5.47%
Apr-22-24 10:15AM	CNS Pharmaceuticals to Participate in the Virtual Investor Lunch Break: The CNSP Opportunity (ACCESSWIRE)
Apr-01-24 11:52PM	CNSP Stock Earnings: CNS Pharmaceuticals Reported Results for Q4 2023 (InvestorPlace) -14.54%
05:00PM	CNS Pharmaceuticals Reports Full Year 2023 Financial Results and Highlights Recent Corporate and Clinical Achievements (ACCESSWIRE)
09:05AM	CNS Pharmaceuticals to Present at Two Investor Conferences in April (ACCESSWIRE)
Jan-29-24 09:00PM	CNS Pharmaceuticals Announces Pricing of $4.0 Million Public Offering (ACCESSWIRE) -20.94% -27.67%
Jan-18-24 08:45AM	Biotech Commercialization Leader, Amy Mahery, to Join CNS Pharmaceuticals Board of Directors (ACCESSWIRE)
Jan-17-24 08:45AM	CNS Pharmaceuticals Achieves Completion of Planned Enrollment in Potentially Pivotal Study of Berubicin for the Treatment of Glioblastoma Multiforme (GBM) (ACCESSWIRE)
Dec-18-23 08:35AM	CNS Pharmaceuticals Announces Successful Interim Analysis of Efficacy and Safety Data in Potentially Pivotal Study of Berubicin (ACCESSWIRE) -23.12%
Dec-06-23 09:00AM	How CNS Pharmaceuticals Is Taking A Different Approach To Find A Treatment For Glioblastoma, A Cancer With A Poor Prognosis And No Cure (ACCESSWIRE)
Nov-22-23 09:05AM	CNS Pharmaceuticals (NASDAQ: CNSP) Presents Updated Safety Data from Ongoing Potentially Pivotal Study Evaluating Berubicin in Advance of the Pre-Planned Interim Analysis of Efficacy (ACCESSWIRE) +7.66%
Nov-16-23 10:00AM	CNS Pharmaceuticals To Release Interim Data By The End Of The Year For Potential Glioblastoma Drug Candidate (ACCESSWIRE) +9.38%
Nov-15-23 08:00AM	CNS Pharmaceuticals Reports Third Quarter 2023 Financial Results and Reiterates Company is on Track to Achieve Milestones for Berubicin Potentially Pivotal Study Before Year End (ACCESSWIRE) +14.97%
Oct-19-23 09:05AM	CNS Pharmaceuticals to Participate at the Virtual Investor Ask the CEO Conference (ACCESSWIRE) +11.24%
Oct-18-23 10:00AM	JTC Team Announces Presenting Company Line Up for the Virtual Investor Ask the CEO Conference Being Held October 24-25, 2023 (ACCESSWIRE) +11.25%
Oct-16-23 09:00AM	Glioblastoma Is the Most Aggressive Type of Brain Cancer, With No Cure - CNS Pharmaceuticals Innovative Approach To Treatment Could Offer Hope (ACCESSWIRE) +20.00%
Oct-11-23 08:45AM	CNS Pharmaceuticals' (NASDAQ:CNSP) Ongoing Potentially Pivotal Study of Berubicin for the Treatment of Glioblastoma Multiforme (GBM) Continues Rapid Pace of Enrollment with 229 Patients Enrolled to Date (ACCESSWIRE) +10.28%
Sep-07-23 08:45AM	CNS Pharmaceuticals (NASDAQ: CNSP) Reaches Milestone with Enrollment of 200 Patients in Ongoing Potentially Pivotal Study of Berubicin with the Treatment of Glioblastoma Multiforme (GBM) (ACCESSWIRE)
Sep-05-23 08:45AM	CNS Pharmaceuticals (NASDAQ: CNSP) to Present at the H.C. Wainwright 25th Annual Global Investment Conference (ACCESSWIRE) -6.51%
Aug-14-23 08:35AM	CNS Pharmaceuticals (NASDAQ: CNSP) Presents Updated Results from On-Going Potentially Pivotal Study of Berubicin in Adult Patients with Recurrent GBM (WHO Grade IV) After Failure of Standard First Line Therapy (ACCESSWIRE) -12.81%
07:35AM	CNS Pharmaceuticals Reports Second Quarter 2023 Financial Results and Reiterates Upcoming Milestones (ACCESSWIRE)
Aug-03-23 08:15AM	CNS Pharmaceuticals to Present at Benzinga's Virtual Biotech Conference (ACCESSWIRE)
08:00AM	CNS Pharmaceuticals Provides Clinical Trial Update for Ongoing Potentially Pivotal Study with Berubicin for the Treatment of Glioblastoma Multiforme (GBM) (ACCESSWIRE)
Jul-27-23 09:05AM	CNS Pharmaceuticals (NASDAQ:CNSP) Announces Acceptance of Abstract for Poster Presentation at the 2023 SNO/ASCO CNS Cancer Conference (ACCESSWIRE)
Jul-05-23 08:45AM	CNS Pharmaceuticals to Participate in the Virtual Investor Summer Spotlight Series (ACCESSWIRE)
Jun-14-23 09:05AM	CNS Pharmaceuticals (NASDAQ:CNSP) to Participate in the Healthcare Virtual Conference Presented by Maxim Group LLC and Hosted by M-Vest (ACCESSWIRE) +9.00%
May-25-23 09:05AM	CNS Pharmaceuticals (NASDAQ:CNSP) Achieves Over 50% Completion of Enrollment in Potentially Pivotal Study with Berubicin for the Treatment of Glioblastoma Multiforme (GBM) (ACCESSWIRE)
May-15-23 08:35AM	CNS Pharmaceuticals Reports First Quarter 2023 Financial Results and Provides Corporate Update (ACCESSWIRE)
May-08-23 08:45AM	Bettina M. Cockroft, M.D., M.B.A., Pharmaceutical and Biotech Industry Veteran, Joins CNS Pharmaceuticals Board of Directors (ACCESSWIRE) -5.99%
May-03-23 08:45AM	CNS Pharmaceuticals Investigating Potential Naked Short Selling; Retains Shareholder Intelligence Services, LLC (ACCESSWIRE) +26.32%
Apr-27-23 08:45AM	CNS Pharmaceuticals to Present at the Virtual Investor Spotlight Event - Rapidly Advancing GBM Pivotal Study (ACCESSWIRE)
Apr-17-23 06:54AM	Daily Vickers Top Buyers & Sellers for 04/17/2023 (Argus Research) +17.02%
Apr-10-23 08:45AM	Over 100 Patients Now Enrolled in CNS Pharmaceuticals (NASDAQ: CNSP) Potentially Pivotal Study Evaluating Berubicin for the Treatment of Glioblastoma Multiforme (GBM) (ACCESSWIRE)
Apr-06-23 09:05AM	CNS Pharmaceuticals Receives Approval from Competent Authority and Central Ethics Committee in Italy for Potentially Pivotal Global Trial Evaluating Berubicin for the Treatment of GBM (ACCESSWIRE) -13.38%
Apr-03-23 08:05AM	CNS Pharmaceuticals Reports Full Year 2022 Financial Results and Provides Corporate Update (ACCESSWIRE)
Mar-29-23 09:05AM	CNS Pharmaceuticals to Present at the Virtual Investor GBM Spotlight Event (PR Newswire)
Mar-13-23 07:05AM	CNS Pharmaceuticals Announces it Has No Exposure to Silicon Valley Bank Issues (PR Newswire) +6.40%
Mar-09-23 09:05AM	CNS Pharmaceuticals Continues Momentum in Ongoing Potentially Pivotal Global Trial Evaluating Berubicin for the Treatment of GBM with First Patient Enrolled in Switzerland (PR Newswire) -8.16%
Feb-07-23 08:45AM	CNS Pharmaceuticals Announces First Patient Enrolled in Spain in Ongoing Potentially Pivotal Global Trial Evaluating Berubicin for the Treatment of GBM (PR Newswire) -7.89%
Jan-12-23 08:45AM	CNS Pharmaceuticals Announces Investigator-Initiated Phase 1b/2 Trial to be Conducted at the Pomeranian Medical University in Poland (PR Newswire) -8.12%
Jan-11-23 01:00PM	JTC Team to Host the Virtual Investor 2023 Companies to Watch Event on January 17th, 18th, and 19th (ACCESSWIRE)
Jan-05-23 09:05AM	CNS Pharmaceuticals to Present at the Virtual Investor 2023 Companies to Watch Event (PR Newswire) -5.52%
Jan-03-23 02:28PM	CNS Pharmaceuticasl appoints new chairperson as clinical development progresses (American City Business Journals) +10.83%
12:00PM	CNS Pharmaceuticals Appoints Faith L. Charles, JD as Chair of the Board of Directors (PR Newswire)
Dec-08-22 09:08AM	CNS Pharmaceuticals Announces Preliminary Results from Ongoing Potentially Pivotal Trial Evaluating Berubicin for the Treatment of Recurrent Glioblastoma Multiforme (GBM) (PR Newswire)
Dec-05-22 08:05AM	CNS Pharmaceuticals to Participate at the Virtual Investor "Ask the CEO" Event (PR Newswire) -7.97%
Nov-30-22 10:00PM	CNS Pharmaceuticals Announces Pricing of $6.0 Million Public Offering At a Premium to the Market Closing Price (PR Newswire) -25.19%
Nov-28-22 04:53PM	CNS Pharmaceuticals Announces Reverse Stock Split (PR Newswire) -20.43% -19.21%
Nov-15-22 01:09PM	Biopharma co. CNS Pharmaceuticals highlights European expansion in Q3 results (American City Business Journals)
Nov-14-22 04:05PM	CNS Pharmaceuticals Reports Third Quarter 2022 Financial Results and Provides Corporate Update (PR Newswire)
Nov-02-22 08:45AM	CNS Pharmaceuticals Announces Dosing of First Patient in Europe/France in Ongoing Potentially Pivotal Global Trial Evaluating Berubicin for the Treatment of GBM (PR Newswire) +17.53%
Oct-10-22 09:00AM	CNS Pharmaceuticals to Participate in The American Brain Tumor Association's Breakthrough (ABTA) for Brain Tumors® 5K (BT5K) Run (PR Newswire)
Oct-07-22 08:00AM	CNS Pharmaceuticals Inc. Featured in Syndicated Broadcast Covering Activation of First Clinical Trial Sites in Europe Evaluating Berubicin for the Treatment of GBM (GlobeNewswire)
Sep-28-22 09:05AM	CNS Pharmaceuticals Announces Activation of First Clinical Trial Sites in Europe for Ongoing Potentially Pivotal Global Trial Evaluating Berubicin for the Treatment of GBM (PR Newswire)
Sep-23-22 09:00AM	CNS Pharmaceuticals to Present at the Virtual Investor Innovations in Oncology - Ongoing Pivotal Global Study for Treatment of Glioblastoma Multiforme (GBM) (PR Newswire)
Sep-07-22 08:45AM	CNS Pharmaceuticals to Present at the H.C. Wainwright 24th Annual Global Investment Conference (PR Newswire)
Aug-15-22 08:05AM	CNS Pharmaceuticals Reports Second Quarter 2022 Financial Results and Provides Corporate Update (PR Newswire)
Jul-25-22 08:05AM	CNS Pharmaceuticals Urges Shareholders to Vote in Favor of Proxy Proposals for the Upcoming Annual Meeting of Shareholders on July 27, 2022 (PR Newswire)
Jun-23-22 08:35AM	CNS Pharmaceuticals Receives Approval from U.S. FDA for Protocol Amendment to Ongoing Potentially Pivotal Global Trial Evaluating Berubicin for the Treatment of GBM (PR Newswire)

CNS Pharmaceuticals, Inc. is a preclinical stage pharmaceutical company, which engages in the development of anticancer drug candidates for the treatment of primary and metastatic brain and central nervous system tumors. Its product pipeline includes berubicin, and CNS-12. The company was founded by Waldemar Priebe in July 2017 and is headquartered in Houston, TX.

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

CNSP

Cns Pharmaceuticals Inc

Upgrade your FINVIZ experience